Provided by Tiger Trade Technology Pte. Ltd.

Pyxis Oncology, Inc.

1.37
-0.1400-9.27%
Post-market: 1.430.0600+4.38%19:19 EST
Volume:714.25K
Turnover:999.62K
Market Cap:85.30M
PE:-0.87
High:1.55
Open:1.52
Low:1.34
Close:1.51
52wk High:5.55
52wk Low:0.8332
Shares:62.26M
Float Shares:41.16M
Volume Ratio:0.78
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5736
EPS(LYR):-1.3231
ROE:-87.28%
ROA:-34.33%
PB:1.24
PE(LYR):-1.04

Loading ...

Pyxis Oncology Announces Interim CEO Amid Leadership Transition

TIPRANKS
·
Feb 07

Pyxis Oncology Appoints Thomas Civik as Interim CEO

Reuters
·
Feb 07

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Pyxis Oncology (PYXS)

TIPRANKS
·
Feb 04

Pyxis Oncology Names Thomas Civik Interim CEO

Reuters
·
Feb 03

Pyxis Oncology Inc - Lara S. Sullivan Steps Down as President, CEO, and Cmo

THOMSON REUTERS
·
Feb 03

Press Release: Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

Dow Jones
·
Feb 03

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

Benzinga_recent_news
·
Dec 19, 2025

Pyxis Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 19, 2025

RBC Cuts Price Target on Pyxis Oncology to $5 From $8, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Dec 19, 2025

Pyxis Oncology, Inc. : H.c. Wainwright Raises Target Price to $7 From $5

THOMSON REUTERS
·
Dec 19, 2025

Pyxis Oncology Slips on Data Suggesting High Incidence of Adverse Effects in Cancer-Drug Trials

Dow Jones
·
Dec 19, 2025

Investors Await Key Inflation, Employment Data as US Futures Rise Thursday Pre-Bell

MT Newswires Live
·
Dec 18, 2025

Pyxis Oncology Reports Positive Preliminary Phase 1 Results for MICVO in Head and Neck Cancer

Reuters
·
Dec 18, 2025

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (Micvo) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

THOMSON REUTERS
·
Dec 18, 2025

Pyxis Oncology Inc: Micvo Was Generally Well Tolerated, With No Grade 4 ADC Payload Treatment-Related Adverse Events of Interest Observed

THOMSON REUTERS
·
Dec 18, 2025

Pyxis Oncology Inc: Micvo Well Tolerated With No Grade 5 Events

THOMSON REUTERS
·
Dec 18, 2025

Pyxis Oncology Files $350 Million Mixed Shelf

MT Newswires Live
·
Nov 26, 2025

Pyxis Oncology Inc Files for Mixed Shelf of up to $350 Mln – SEC Filing

THOMSON REUTERS
·
Nov 26, 2025

Pyxis Oncology Inc - Files for $150 Mln Stock Sale Agreement With Leerink Partners - SEC Filing

THOMSON REUTERS
·
Nov 26, 2025

Pyxis Oncology Inc : Leerink Partners Raises Target Price to $9 From $7

THOMSON REUTERS
·
Nov 25, 2025